

REFERENCES

1. Ho, D.D., et al., *Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection*. Nature, 1995. 373(6510): p. 123-6.
2. Perelson, A.S., et al., *HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time*. Science, 1996. 271(5255): p. 1582-6.
3. Taylor, B.S., et al., *The challenge of HIV-1 subtype diversity*. N Engl J Med, 2008. 358(15): p. 1590-602.
4. UNAIDS, *World AIDS Day 2014 Report*, in *World AIDS Day 2014 Report - Fact sheet*. 2015.
5. Kalish, M.L., et al., *Early HIV type 1 strains in Thailand were not responsible for the current epidemic*. AIDS Res Hum Retroviruses, 1994. 10(11): p. 1573-5.
6. Ou, C.Y., et al., *Independent introduction of two major HIV-1 genotypes into distinct high-risk populations in Thailand*. Lancet, 1993. 341(8854): p. 1171-4.
7. Kalish, M.L., et al., *The evolving molecular epidemiology of HIV-1 envelope subtypes in injecting drug users in Bangkok, Thailand: implications for HIV vaccine trials*. AIDS, 1995. 9(8): p. 851-7.
8. Subbarao, S., et al., *HIV type 1 in Thailand, 1994-1995: persistence of two subtypes with low genetic diversity*. AIDS Res Hum Retroviruses, 1998. 14(4): p. 319-27.
9. Tovanabutra, S., et al., *A new circulating recombinant form, CRF15_01B, reinforces the linkage between IDU and heterosexual epidemics in Thailand*. AIDS Res Hum Retroviruses, 2003. 19(7): p. 561-7.

10. Rutvisuttinunt, W., et al., *Two unique recombinant forms identified in incident HIV type 1 infections in Thai blood donors*. AIDS Res Hum Retroviruses, 2012. 28(12): p. 1703-11.
11. Tovanabutra, S., et al., *Identification of CRF34_01B, a second circulating recombinant form unrelated to and more complex than CRF15_01B, among injecting drug users in northern Thailand*. AIDS Res Hum Retroviruses, 2007. 23(6): p. 829-33.
12. Li, Y., et al., *Identification of a novel second-generation circulating recombinant form (CRF48_01B) in Malaysia: a descendant of the previously identified CRF33_01B*. J Acquir Immune Defic Syndr, 2010. 54(2): p. 129-36.
13. Ng, O.T., et al., *Identification of new CRF51_01B in Singapore using full genome analysis of three HIV type 1 isolates*. AIDS Res Hum Retroviruses, 2012. 28(5): p. 527-30.
14. Liu, Y., et al., *Identification of a novel HIV type 1 circulating recombinant form (CRF52_01B) in Southeast Asia*. AIDS Res Hum Retroviruses, 2012. 28(10): p. 1357-61.
15. Chow, W.Z., et al., *Genome sequences of a novel HIV-1 CRF53_01B identified in Malaysia*. J Virol, 2012. 86(20): p. 11398-9.
16. Ng, K.T., et al., *Genome sequence of a novel HIV-1 circulating recombinant form 54_01B from Malaysia*. J Virol, 2012. 86(20): p. 11405-6.
17. Han, X., et al., *Genome Sequences of a Novel HIV-1 Circulating Recombinant Form, CRF55_01B, Identified in China*. Genome Announc, 2013. 1(1).
18. Chow, W.Z., et al., *A newly emerging HIV-1 recombinant lineage (CRF58_01B) disseminating among people who inject drugs in Malaysia*. PLoS One, 2014. 9(1): p. e85250.

19. Han, X., et al., *Genome Sequences of a Novel HIV-1 Circulating Recombinant Form (CRF59_01B) Identified among Men Who Have Sex with Men in Northeastern China*. *Genome Announc*, 2013. 1(3).
20. Wu, J., et al., *New emerging recombinant HIV-1 strains and close transmission linkage of HIV-1 strains in the Chinese MSM population indicate a new epidemic risk*. *PLoS One*, 2013. 8(1): p. e54322.
21. Liu, J., et al., *Phylogenetics of HIV-1 unique recombinant forms in China-Myanmar border: implication for HIV-1 transmission to Myanmar from Dehong, China*. *Infect Genet Evol*, 2012. 12(8): p. 1944-8.
22. Li T, L.Y., Han Y, Xie J, Gu L, Li L, Li W, Wang H, Ishida T, Iwamoto A , , *CRF01_AE Subtype Is Associated with Faster Disease Progression in Chinese HIV-1 Sexually Infected Patients in Conference on Retroviruses and Opportunistic Infections 2013*. 2013: Atlanta, USA.
23. Conti, L., et al., *Immunomodulatory effects of the HIV-1 gp120 protein on antigen presenting cells: implications for AIDS pathogenesis*. *Immunobiology*, 2004. 209(1-2): p. 99-115.
24. Gottlieb MS, S.H., Fan PT, Saxon A, Weisman JD, *Pneumocystis pneumonia--Los Angeles*. *MMWR Morb Mortal Wkly Rep*, 1981. 30(21): p. 250-2.
25. (CDC)., C.f.D.C.a.P., *Kaposi's sarcoma and Pneumocystis pneumonia among homosexual men--New York City and California*. *MMWR Morb Mortal Wkly Rep*, 1981. 30(25): p. 305-8.
26. Barre-Sinoussi, F., et al., *Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)*. *Science*, 1983. 220(4599): p. 868-71.
27. Popovic, M., et al., *Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS*. *Science*, 1984. 224(4648): p. 497-500.

28. Levy, J.A., et al., *Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS*. Science, 1984. 225(4664): p. 840-2.
29. Coffin, J., et al., *What to call the AIDS virus?* Nature, 1986. 321(6065): p. 10.
30. Barin, F., et al., *Serological evidence for virus related to simian T-lymphotropic retrovirus III in residents of west Africa*. Lancet, 1985. 2(8469-70): p. 1387-9.
31. Clavel, F., et al., *[LAV type II: a second retrovirus associated with AIDS in West Africa]*. C R Acad Sci III, 1986. 302(13): p. 485-8.
32. Chan, D.C., et al., *Core structure of gp41 from the HIV envelope glycoprotein*. Cell, 1997. 89(2): p. 263-73.
33. Gelderblom, H.R., M. Ozel, and G. Pauli, *Morphogenesis and morphology of HIV. Structure-function relations*. Arch Virol, 1989. 106(1-2): p. 1-13.
34. Ganser-Pornillos, B.K., M. Yeager, and W.I. Sundquist, *The structural biology of HIV assembly*. Curr Opin Struct Biol, 2008. 18(2): p. 203-17.
35. Hirsch, M.S., et al., *Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel*. JAMA, 1998. 279(24): p. 1984-91.
36. Zhou, T., et al., *Structural definition of a conserved neutralization epitope on HIV-1 gp120*. Nature, 2007. 445(7129): p. 732-7.
37. Frost, S.D., et al., *Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection*. Proc Natl Acad Sci U S A, 2005. 102(51): p. 18514-9.
38. Sheehy, A.M., N.C. Gaddis, and M.H. Malim, *The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif*. Nat Med, 2003. 9(11): p. 1404-7.

39. Sheehy, A.M., et al., *Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein*. Nature, 2002. 418(6898): p. 646-50.
40. Bour, S. and K. Strebel, *The HIV-1 Vpu protein: a multifunctional enhancer of viral particle release*. Microbes Infect, 2003. 5(11): p. 1029-39.
41. Willey, R.L., et al., *Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4*. J Virol, 1992. 66(12): p. 7193-200.
42. Rhodes, D.I., et al., *Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression*. Australian Long-Term Nonprogressor Study Group. J Virol, 2000. 74(22): p. 10581-8.
43. Salvi, R., et al., *Grossly defective nef gene sequences in a human immunodeficiency virus type 1-seropositive long-term nonprogressor*. J Virol, 1998. 72(5): p. 3646-57.
44. Watts, J.M., et al., *Architecture and secondary structure of an entire HIV-1 RNA genome*. Nature, 2009. 460(7256): p. 711-6.
45. Weiss, R.A., *HIV and AIDS in relation to other pandemics. Among the viruses plaguing humans, HIV is a recent acquisition. Its outstanding success as an infection poses immense scientific challenges to human health and raises the question "What comes next?"*. EMBO Rep, 2003. 4 Spec No: p. S10-4.
46. Wei, X., et al., *Viral dynamics in human immunodeficiency virus type 1 infection*. Nature, 1995. 373(6510): p. 117-22.
47. Ji, J.P. and L.A. Loeb, *Fidelity of HIV-1 reverse transcriptase copying RNA in vitro*. Biochemistry, 1992. 31(4): p. 954-8.
48. Arnold, E. and S.G. Sarafianos, *Molecular biology: an HIV secret uncovered*. Nature, 2008. 453(7192): p. 169-70.

49. Russell, R.A., et al., *APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA*. *Retrovirology*, 2009. 6: p. 16.
50. Cullen, B.R., *HIV-1 auxiliary proteins: making connections in a dying cell*. *Cell*, 1998. 93(5): p. 685-92.
51. Gao, F., et al., *Origin of HIV-1 in the chimpanzee *Pan troglodytes troglodytes**. *Nature*, 1999. 397(6718): p. 436-41.
52. Peeters, M., et al., *Isolation and partial characterization of an HIV-related virus occurring naturally in chimpanzees in Gabon*. *AIDS*, 1989. 3(10): p. 625-30.
53. Chen, Z., et al., *Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop*. *J Virol*, 1996. 70(6): p. 3617-27.
54. Chen, Z., et al., *Human immunodeficiency virus type 2 (HIV-2) seroprevalence and characterization of a distinct HIV-2 genetic subtype from the natural range of simian immunodeficiency virus-infected sooty mangabeys*. *J Virol*, 1997. 71(5): p. 3953-60.
55. Simon, F., et al., *Identification of a new human immunodeficiency virus type 1 distinct from group M and group O*. *Nat Med*, 1998. 4(9): p. 1032-7.
56. Vallari, A., et al., *Confirmation of putative HIV-1 group P in Cameroon*. *J Virol*, 2010. 85(3): p. 1403-7.
57. Keele, B.F., et al., *Chimpanzee reservoirs of pandemic and nonpandemic HIV-1*. *Science*, 2006. 313(5786): p. 523-6.

58. Yamaguchi, J., et al., *Evaluation of HIV type 1 group O isolates: identification of five phylogenetic clusters*. AIDS Res Hum Retroviruses, 2002. 18(4): p. 269-82.
59. Worobey, M., et al., *Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960*. Nature, 2008. 455(7213): p. 661-4.
60. Santoro, M.M. and C.F. Perno, *HIV-1 Genetic Variability and Clinical Implications*. ISRN Microbiol, 2013. 2013: p. 481314.
61. Vidal, N., et al., *Identification and molecular characterization of subsubtype A4 in central Africa*. AIDS Res Hum Retroviruses, 2006. 22(2): p. 182-7.
62. Takeb, E.Y., S. Kusagawa, and K. Motomura, *Molecular epidemiology of HIV: tracking AIDS pandemic*. Pediatr Int, 2004. 46(2): p. 236-44.
63. Thomson, M.M., L. Perez-Alvarez, and R. Najera, *Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy*. Lancet Infect Dis, 2002. 2(8): p. 461-71.
64. Korber, B., et al., *Evolutionary and immunological implications of contemporary HIV-1 variation*. Br Med Bull, 2001. 58: p. 19-42.
65. Rotta, I. and S.M. Almeida, *Genotypical diversity of HIV clades and central nervous system impairment*. Arq Neuropsiquiatr, 2012. 69(6): p. 964-72.
66. Streeck, H., et al., *Immune-driven recombination and loss of control after HIV superinfection*. J Exp Med, 2008. 205(8): p. 1789-96.
67. Moutouh, L., J. Corbeil, and D.D. Richman, *Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure*. Proc Natl Acad Sci U S A, 1996. 93(12): p. 6106-11.
68. Robertson, D.L., et al., *HIV-1 nomenclature proposal*. Science, 2000. 288(5463): p. 55-6.

69. Goodenow, M., et al., *HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions*. J Acquir Immune Defic Syndr, 1989. 2(4): p. 344-52.
70. Mansky, L.M. and H.M. Temin, *Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase*. J Virol, 1995. 69(8): p. 5087-94.
71. Simon-Loriere, E., et al., *Molecular mechanisms of recombination restriction in the envelope gene of the human immunodeficiency virus*. PLoS Pathog, 2009. 5(5): p. e1000418.
72. Hemelaar, J., et al., *Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004*. AIDS, 2006. 20(16): p. W13-23.
73. Nowak, M., *HIV mutation rate*. Nature, 1990. 347(6293): p. 522.
74. Gao, F., et al., *Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious*. J Virol, 2004. 78(5): p. 2426-33.
75. Grobler, J., et al., *Incidence of HIV-1 dual infection and its association with increased viral load set point in a cohort of HIV-1 subtype C-infected female sex workers*. J Infect Dis, 2004. 190(7): p. 1355-9.
76. Gottlieb, G.S., et al., *Dual HIV-1 infection associated with rapid disease progression*. Lancet, 2004. 363(9409): p. 619-22.
77. Lau, K.A. and J.J. Wong, *Current Trends of HIV Recombination Worldwide*. Infect Dis Rep, 2013. 5(Suppl 1): p. e4.
78. Casado, G., et al., *Identification of a novel HIV-1 circulating ADG intersubtype recombinant form (CRF19_cpx) in Cuba*. J Acquir Immune Defic Syndr, 2005. 40(5): p. 532-7.

79. Carr, J.K., et al., *Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants*. Virology, 1998. 247(1): p. 22-31.
80. Jetzt, A.E., et al., *High rate of recombination throughout the human immunodeficiency virus type 1 genome*. J Virol, 2000. 74(3): p. 1234-40.
81. Fan, J., M. Negroni, and D.L. Robertson, *The distribution of HIV-1 recombination breakpoints*. Infect Genet Evol, 2007. 7(6): p. 717-23.
82. Baird, H.A., et al., *Sequence determinants of breakpoint location during HIV-1 intersubtype recombination*. Nucleic Acids Res, 2006. 34(18): p. 5203-16.
83. Gao, F., et al., *The heterosexual human immunodeficiency virus type 1 epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin*. J Virol, 1996. 70(10): p. 7013-29.
84. van Harmelen, J., et al., *An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa*. AIDS, 1997. 11(1): p. 81-7.
85. Avila, M.M., et al., *Two HIV-1 epidemics in Argentina: different genetic subtypes associated with different risk groups*. J Acquir Immune Defic Syndr, 2002. 29(4): p. 422-6.
86. Renjifo, B., et al., *Differences in perinatal transmission among human immunodeficiency virus type 1 genotypes*. J Hum Virol, 2001. 4(1): p. 16-25.
87. Renjifo, B., et al., *In-utero transmission of quasispecies among human immunodeficiency virus type 1 genotypes*. Virology, 2003. 307(2): p. 278-82.
88. McCutchan, F.E., *Global epidemiology of HIV*. J Med Virol, 2006. 78 Suppl 1: p. S7-S12.
89. Taylor, G.P. and N. Low-Beer, *Antiretroviral therapy in pregnancy: a focus on safety*. Drug Saf, 2001. 24(9): p. 683-702.

90. Hu, D.J., et al., *Viral load differences in early infection with two HIV-1 subtypes*. AIDS, 2001. 15(6): p. 683-91.
91. Gray, C.M., et al., *Viral dynamics and CD4+ T cell counts in subtype C human immunodeficiency virus type 1-infected individuals from southern Africa*. AIDS Res Hum Retroviruses, 2005. 21(4): p. 285-91.
92. Jeeninga, R.E., et al., *Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G*. J Virol, 2000. 74(8): p. 3740-51.
93. Tscherning, C., et al., *Differences in chemokine coreceptor usage between genetic subtypes of HIV-1*. Virology, 1998. 241(2): p. 181-8.
94. Berger, E.A., et al., *A new classification for HIV-1*. Nature, 1998. 391(6664): p. 240.
95. Huang, W., et al., *Coreceptor tropism in human immunodeficiency virus type 1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations*. J Virol, 2007. 81(15): p. 7885-93.
96. Cilliers, T., et al., *The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C*. J Virol, 2003. 77(7): p. 4449-56.
97. Kaleebu, P., et al., *Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda*. J Infect Dis, 2002. 185(9): p. 1244-50.
98. Kiwanuka, N., et al., *Effect of human immunodeficiency virus Type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection*. J Infect Dis, 2008. 197(5): p. 707-13.
99. Kanki, P.J., et al., *Human immunodeficiency virus type 1 subtypes differ in disease progression*. J Infect Dis, 1999. 179(1): p. 68-73.

100. Vasan, A., et al., *Different rates of disease progression of HIV type 1 infection in Tanzania based on infecting subtype*. Clin Infect Dis, 2006. 42(6): p. 843-52.
101. Easterbrook, P.J., et al., *Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy*. J Int AIDS Soc, 2010. 13: p. 4.
102. Weisman, Z., et al., *Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds*. J Acquir Immune Defic Syndr, 1999. 21(2): p. 157-63.
103. Alaeus, A., et al., *Similar rate of disease progression among individuals infected with HIV-1 genetic subtypes A-D*. AIDS, 1999. 13(8): p. 901-7.
104. Amornkul, P.N., et al., *Clinical disease associated with HIV-1 subtype B' and E infection among 2104 patients in Thailand*. AIDS, 1999. 13(14): p. 1963-9.
105. Laurent, C., et al., *No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study*. J Infect Dis, 2002. 186(4): p. 486-92.
106. Rayfield, M.A., et al., *HIV-1 group O virus identified for the first time in the United States*. Emerg Infect Dis, 1996. 2(3): p. 209-12.
107. Parry, J.V., et al., *Towards error-free HIV diagnosis: guidelines on laboratory practice*. Commun Dis Public Health, 2003. 6(4): p. 334-50.
108. Loussert-Ajaka, I., et al., *HIV-1 detection in cervicovaginal secretions during pregnancy*. AIDS, 1997. 11(13): p. 1575-81.
109. Weber, B., et al., *Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays*. J Clin Microbiol, 1998. 36(8): p. 2235-9.

110. Aghokeng, A.F., et al., *Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon*. PLoS One, 2009. 4(11): p. e7702.
111. Kwon, J.A., et al., *Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays*. J Virol Methods, 2006. 133(1): p. 20-6.
112. Koch, W.H., et al., *Evaluation of United States-licensed human immunodeficiency virus immunoassays for detection of group M viral variants*. J Clin Microbiol, 2001. 39(3): p. 1017-20.
113. Rouet, F., et al., *Field evaluation of a rapid human immunodeficiency virus (HIV) serial serologic testing algorithm for diagnosis and differentiation of HIV type 1 (HIV-1), HIV-2, and dual HIV-1-HIV-2 infections in West African pregnant women*. J Clin Microbiol, 2004. 42(9): p. 4147-53.
114. Koblavi-Deme, S., et al., *Sensitivity and specificity of human immunodeficiency virus rapid serologic assays and testing algorithms in an antenatal clinic in Abidjan, Ivory Coast*. J Clin Microbiol, 2001. 39(5): p. 1808-12.
115. Swanson, P., et al., *Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses*. J Virol Methods, 2007. 141(1): p. 49-57.
116. Hemelaar, J., *The origin and diversity of the HIV-1 pandemic*. Trends Mol Med, 2011. 18(3): p. 182-92.
117. Kim, J.E., et al., *Short communication: identification of a novel HIV type 1 subtype H/J recombinant in Canada with discordant HIV viral load (RNA) values in three different commercial assays*. AIDS Res Hum Retroviruses, 2007. 23(11): p. 1309-13.

118. Palmer, S., et al., *Tenofovir, adefovir, and zidovudine susceptibilities of primary human immunodeficiency virus type 1 isolates with non-B subtypes or nucleoside resistance*. AIDS Res Hum Retroviruses, 2001. 17(12): p. 1167-73.
119. Poveda, E., et al., *Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes*. AIDS, 2008. 22(5): p. 611-6.
120. Abecasis, A.B., et al., *Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02_AG*. Antivir Ther, 2006. 11(5): p. 581-9.
121. Beerenwinkel, N., et al., *Estimating HIV evolutionary pathways and the genetic barrier to drug resistance*. J Infect Dis, 2005. 191(11): p. 1953-60.
122. Brenner, B., et al., *A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors*. AIDS, 2003. 17(1): p. F1-5.
123. Turner, D., et al., *Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1*. Antimicrob Agents Chemother, 2004. 48(8): p. 2993-8.
124. van de Vijver, D.A., et al., *The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes*. J Acquir Immune Defic Syndr, 2006. 41(3): p. 352-60.
125. Descamps, D., et al., *Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses*. J Virol, 1997. 71(11): p. 8893-8.
126. Quinones-Mateu, M.E., et al., *Analysis of pol gene heterogeneity, viral quasiespecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1*. J Virol, 1998. 72(11): p. 9002-15.

127. Goulder, P.J., et al., *Evolution and transmission of stable CTL escape mutations in HIV infection*. Nature, 2001. 412(6844): p. 334-8.
128. Kwong, P.D., et al., *HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites*. Nature, 2002. 420(6916): p. 678-82.
129. Girard, M.P., S.K. Osmanov, and M.P. Kieny, *A review of vaccine research and development: the human immunodeficiency virus (HIV)*. Vaccine, 2006. 24(19): p. 4062-81.
130. Douek, D.C., P.D. Kwong, and G.J. Nabel, *The rational design of an AIDS vaccine*. Cell, 2006. 124(4): p. 677-81.
131. Family Health International (FHI) and Bureau of AIDS, T.a.S., Department of Disease Control, Ministry of Public and T. Health, *The Asian Epidemic Model (AEM) Projections for HIV/AIDS in Thailand: 2005-2025*. 2009.
132. Essex, M., *Human immunodeficiency viruses in the developing world*. Adv Virus Res, 1999. 53: p. 71-88.
133. Luo, C.C., et al., *HIV-1 subtype C in China*. Lancet, 1995. 345(8956): p. 1051-2.
134. Piyasirisilp, S., et al., *A recent outbreak of human immunodeficiency virus type 1 infection in southern China was initiated by two highly homogeneous, geographically separated strains, circulating recombinant form AE and a novel BC recombinant*. J Virol, 2000. 74(23): p. 11286-95.
135. Soares, E.A., et al., *HIV-1 subtype C dissemination in southern Brazil*. AIDS, 2005. 19 Suppl 4: p. S81-6.
136. Wang, W., et al., *The dynamic face of HIV-1 subtypes among men who have sex with men in Beijing, China*. Curr HIV Res, 2011. 9(2): p. 136-9.

137. Wang, W., et al., *Identification of subtype B, multiple circulating recombinant forms and unique recombinants of HIV type 1 in an MSM cohort in China*. AIDS Res Hum Retroviruses, 2008. 24(10): p. 1245-54.
138. Zhao, J., et al., *Origin and outbreak of HIV-1 CRF55_01B among MSM in Shenzhen, China*. J Acquir Immune Defic Syndr, 2014. 66(3): p. e65-7.
139. Guo, H., et al., *Rapidly increasing prevalence of HIV and syphilis and HIV-1 subtype characterization among men who have sex with men in Jiangsu, China*. Sex Transm Dis, 2009. 36(2): p. 120-5.
140. Han, X., et al., *High prevalence of HIV-1 intersubtype B'/C recombinants among injecting drug users in Dehong, China*. PLoS One, 2013. 8(5): p. e65337.
141. Su, Y.Z., et al., *Update on diversity and distribution of HIV-1 subtypes in Yunnan province*. Epidemiol Infect, 2013. 141(11): p. 2418-27.
142. Chen, M., et al., *Genetic diversity and drug resistance among newly diagnosed and antiretroviral treatment-naïve HIV-infected individuals in western Yunnan: a hot area of viral recombination in China*. BMC Infect Dis, 2012. 12: p. 382.
143. Chen, M., et al., *HIV-1 genetic characteristics and transmitted drug resistance among men who have sex with men in Kunming, China*. PLoS One, 2014. 9(1): p. e87033.
144. Pang, W., et al., *Extensive and complex HIV-1 recombination between B', C and CRF01_AE among IDUs in south-east Asia*. AIDS, 2012. 26(9): p. 1121-9.
145. Paladin, F.J., et al., *Genetic subtypes of HIV-1 in the Philippines*. AIDS, 1998. 12(3): p. 291-300.
146. Sahbandar, I.N., et al., *Current HIV type 1 molecular epidemiology profile and identification of unique recombinant forms in Jakarta, Indonesia*. AIDS Res Hum Retroviruses, 2009. 25(7): p. 637-46.

147. Merati, T.P., et al., *CRF01_AE dominates the HIV-1 epidemic in Indonesia*. Sex Health, 2012. 9(5): p. 414-21.
148. Watanaveeradej, V., et al., *Molecular epidemiology of HIV Type 1 in preparation for a Phase III prime-boost vaccine trial in Thailand and a new approach to HIV Type 1 genotyping*. AIDS Res Hum Retroviruses, 2006. 22(8): p. 801-7.
149. Kijak, G.H., et al., *Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial*. J Virol, 2013. 87(13): p. 7265-81.
150. Barin, F., et al., *Diversity of antibody binding to V3 peptides representing consensus sequences of HIV type 1 genotypes A to E: an approach for HIV type 1 serological subtyping*. AIDS Res Hum Retroviruses, 1996. 12(13): p. 1279-89.
151. Sirirungsi W, G.J., Achalapong J, Taiyaitiang C, Leelanitkul P, Lorenz S, Prommas S, Barin F, Lallemand M, Ngo-Giang-Huong N, *HIV-1 serotypes among HIV-1 infected pregnant women in Thailand: a survey over 12 years.*, in *6th IAS Conference on HIV Pathogenesis, Treatment and Prevention*. 17-20 July 2011: Rome, Italy.
152. Praparattanapan, J., et al., *Current molecular epidemiology and recombination of HIV type 1 subtypes in northern Thailand*. AIDS Res Hum Retroviruses, 2011. 27(11): p. 1201-6.
153. สำนักนโยบายและยุทธศาสตร์, ก. and กระทรวงสาธารณสุข, สถิติสาธารณสุข พ.ศ 2554. 2554, กรุงเทพฯ :องค์การสงเคราะห์ทหารผ่านศึก .223.
154. Tamura, K., et al., *MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods*. Mol Biol Evol, 2011. 28(10): p. 2731-9.

155. Samleerat, T., et al., *Characteristics of HIV type 1 (HIV-1) glycoprotein 120 env sequences in mother-infant pairs infected with HIV-1 subtype CRF01_AE*. J Infect Dis, 2008. 198(6): p. 868-76.
156. Wei, H., et al., *Genome sequence of a novel HIV-1 circulating recombinant form (CRF57_BC) identified from Yunnan, China*. AIDS Res Hum Retroviruses, 2014. 30(4): p. 384-8.
157. Wei, H., et al., *Identification of a novel HIV-1 circulating recombinant form (CRF62_BC) in western Yunnan of China*. AIDS Res Hum Retroviruses, 2014. 30(4): p. 380-3.
158. Phanuphak, N., et al., *HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials*. AIDS Res Hum Retroviruses, 2015.
159. Sukasem, C., et al., *Genotypic resistance profiles in antiretroviral-naive HIV-1 infections before and after initiation of first-line HAART: impact of polymorphism on resistance to therapy*. Int J Antimicrob Agents, 2008. 31(3): p. 277-81.
160. Vidal, N., et al., *Unprecedented degree of human immunodeficiency virus type 1 (HIV-1) group M genetic diversity in the Democratic Republic of Congo suggests that the HIV-1 pandemic originated in Central Africa*. J Virol, 2000. 74(22): p. 10498-507.
161. Anderson, J.P., et al., *Testing the hypothesis of a recombinant origin of human immunodeficiency virus type 1 subtype E*. J Virol, 2000. 74(22): p. 10752-65.
162. Murphy, E., et al., *Diversity of V3 region sequences of human immunodeficiency viruses type 1 from the central African Republic*. AIDS Res Hum Retroviruses, 1993. 9(10): p. 997-1006.
163. Nouhin, J., et al., *Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study*. Infect Genet Evol, 2011. 11(1): p. 38-43.